Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies

H. L. Lewis, M. A. Ghasabeh, P. Khoshpouri, Ihab R Kamel, T. M. Pawlik

Research output: Contribution to journalReview article

Abstract

Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size. As imaging modalities and solid tumor therapies continue to advance, there has been growing recognition that measurement of actual tumoricidal activity may not always be related to tumor size, and accurate assessment of treatment response may vary by therapeutic modality. As such, the objective change in the physical size characteristics of a tumor may not accurately reflect biological response to treatment. Functional imaging encompasses methods that are capable of detecting or measuring changes in tissue metabolism, blood flow, or composition. Conventional imaging modalities such as magnetic resonance imaging (MRI) and computed topography (CT) now include techniques such as diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) maps, dynamic contrast enhancement (DCE-MRI), and perfusion CT (pCT). Use of functional cross-sectional imaging is particularly relevant to assess primary and secondary hepatic malignancies treated with LRT, such as trans-arterial chemoembolization (TACE), radiofrequency ablation (RFA), yttrium-90 (Y-90), and hepatic arterial infusion (HAI) chemotherapy. We herein review the imaging techniques, as well as the methodologies for measuring tumor response and survival, among patients treated with LRT for primary and secondary hepatic malignancies.

Original languageEnglish (US)
Pages (from-to)411-422
Number of pages12
JournalSurgical Oncology
Volume26
Issue number4
DOIs
StatePublished - Dec 1 2017

Fingerprint

Biomarkers
Liver
Neoplasms
Therapeutics
Yttrium
Magnetic Resonance Angiography
Magnetic Resonance Imaging
Guidelines
Drug Therapy
Survival
Response Evaluation Criteria in Solid Tumors

Keywords

  • Biomarker
  • Cancer
  • Imaging
  • Outcomes

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. / Lewis, H. L.; Ghasabeh, M. A.; Khoshpouri, P.; Kamel, Ihab R; Pawlik, T. M.

In: Surgical Oncology, Vol. 26, No. 4, 01.12.2017, p. 411-422.

Research output: Contribution to journalReview article

Lewis, H. L. ; Ghasabeh, M. A. ; Khoshpouri, P. ; Kamel, Ihab R ; Pawlik, T. M. / Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. In: Surgical Oncology. 2017 ; Vol. 26, No. 4. pp. 411-422.
@article{16a657d20b444fce9eb882866fa72930,
title = "Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies",
abstract = "Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size. As imaging modalities and solid tumor therapies continue to advance, there has been growing recognition that measurement of actual tumoricidal activity may not always be related to tumor size, and accurate assessment of treatment response may vary by therapeutic modality. As such, the objective change in the physical size characteristics of a tumor may not accurately reflect biological response to treatment. Functional imaging encompasses methods that are capable of detecting or measuring changes in tissue metabolism, blood flow, or composition. Conventional imaging modalities such as magnetic resonance imaging (MRI) and computed topography (CT) now include techniques such as diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) maps, dynamic contrast enhancement (DCE-MRI), and perfusion CT (pCT). Use of functional cross-sectional imaging is particularly relevant to assess primary and secondary hepatic malignancies treated with LRT, such as trans-arterial chemoembolization (TACE), radiofrequency ablation (RFA), yttrium-90 (Y-90), and hepatic arterial infusion (HAI) chemotherapy. We herein review the imaging techniques, as well as the methodologies for measuring tumor response and survival, among patients treated with LRT for primary and secondary hepatic malignancies.",
keywords = "Biomarker, Cancer, Imaging, Outcomes",
author = "Lewis, {H. L.} and Ghasabeh, {M. A.} and P. Khoshpouri and Kamel, {Ihab R} and Pawlik, {T. M.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.suronc.2017.08.004",
language = "English (US)",
volume = "26",
pages = "411--422",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies

AU - Lewis, H. L.

AU - Ghasabeh, M. A.

AU - Khoshpouri, P.

AU - Kamel, Ihab R

AU - Pawlik, T. M.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size. As imaging modalities and solid tumor therapies continue to advance, there has been growing recognition that measurement of actual tumoricidal activity may not always be related to tumor size, and accurate assessment of treatment response may vary by therapeutic modality. As such, the objective change in the physical size characteristics of a tumor may not accurately reflect biological response to treatment. Functional imaging encompasses methods that are capable of detecting or measuring changes in tissue metabolism, blood flow, or composition. Conventional imaging modalities such as magnetic resonance imaging (MRI) and computed topography (CT) now include techniques such as diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) maps, dynamic contrast enhancement (DCE-MRI), and perfusion CT (pCT). Use of functional cross-sectional imaging is particularly relevant to assess primary and secondary hepatic malignancies treated with LRT, such as trans-arterial chemoembolization (TACE), radiofrequency ablation (RFA), yttrium-90 (Y-90), and hepatic arterial infusion (HAI) chemotherapy. We herein review the imaging techniques, as well as the methodologies for measuring tumor response and survival, among patients treated with LRT for primary and secondary hepatic malignancies.

AB - Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size. As imaging modalities and solid tumor therapies continue to advance, there has been growing recognition that measurement of actual tumoricidal activity may not always be related to tumor size, and accurate assessment of treatment response may vary by therapeutic modality. As such, the objective change in the physical size characteristics of a tumor may not accurately reflect biological response to treatment. Functional imaging encompasses methods that are capable of detecting or measuring changes in tissue metabolism, blood flow, or composition. Conventional imaging modalities such as magnetic resonance imaging (MRI) and computed topography (CT) now include techniques such as diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) maps, dynamic contrast enhancement (DCE-MRI), and perfusion CT (pCT). Use of functional cross-sectional imaging is particularly relevant to assess primary and secondary hepatic malignancies treated with LRT, such as trans-arterial chemoembolization (TACE), radiofrequency ablation (RFA), yttrium-90 (Y-90), and hepatic arterial infusion (HAI) chemotherapy. We herein review the imaging techniques, as well as the methodologies for measuring tumor response and survival, among patients treated with LRT for primary and secondary hepatic malignancies.

KW - Biomarker

KW - Cancer

KW - Imaging

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=85028952048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028952048&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2017.08.004

DO - 10.1016/j.suronc.2017.08.004

M3 - Review article

C2 - 29113660

AN - SCOPUS:85028952048

VL - 26

SP - 411

EP - 422

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 4

ER -